Annual report pursuant to Section 13 and 15(d)

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)		1 Months Ended			12 Months Ended					77 Months Ended
	Mar. 03, 2017 $ / shares shares	Mar. 31, 2017 $ / shares shares	Sep. 30, 2016 USD ($) $ / shares shares	Mar. 31, 2015 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2017 USD ($) $ / shares shares	Jan. 01, 2018 USD ($)	Aug. 31, 2011 USD ($)
Notes Payable, Fair Value Disclosure						$ 2,400,000	$ 61,600,000			$ 2,400,000
Derivative Liability						$ 63,000	63,000			$ 63,000
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares						$ 1.19				$ 1.19
Impairment of Long-Lived Assets to be Disposed of						$ 0	$ 0	$ 0
PPCO [Member] \| Platinum Loan Agreement [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability						0				$ 0
PPCO [Member] \| Platinum Loan Agreement [Member] \| Fair Value, Inputs, Level 3 [Member]
Embedded Derivative, Fair Value of Embedded Derivative Liability						$ 0				$ 0
Accounting Standards Update 2014-09 [Member] \| Subsequent Event [Member]
Deferred Revenue											$ 100,000
Accounting Standards Update 2014-09 [Member] \| Subsequent Event [Member] \| Retained Earnings [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption											$ (100,000)
Accounting Standards Update 2016-18 [Member] \| Subsequent Event [Member] \| Fiscal Year 2016 [Member]
Prior Period Reclassification Adjustment					$ 5,000,000
Nonsoftware License Arrangement [Member] \| SpePharm AG [Member]
Deferred Revenue, Additions				$ 2,000,000
Deferred Revenue, Recognition Period				2 years
Deferred Revenue, Revenue Recognized			$ 417,000
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares						$ 0.01				$ 0.01
Finite-Lived Intangible Asset, Useful Life						5 years
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares						$ 3.04				$ 3.04
Finite-Lived Intangible Asset, Useful Life						15 years
The 2002 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized \| shares						12,000,000				12,000,000
The 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized \| shares						5,000,000				5,000,000
The 2002 and 2014 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period						10 years
The 2002 and 2014 Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						1 year
The 2002 and 2014 Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						4 years
The 2016 Plan [Member] \| Employee Stock Option [Member] \| Scenario, Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized \| shares			10,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			100.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price \| $ / shares			$ 2.50
Cardinal Health 414 [Member] \| Lymphoseek [Member]
Sales Revenue, Percent of Sales Made to Entity							99.00%	99.00%
Series NN Warrants [Member]
Class of Warrant or Right, Term		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		$ 1.50				$ 1.50				$ 1.50
Share-based Compensation Arrangement By Share-based Payment Award Award, Vesting, Threshold Consecutive Trading Days			5
Series NN Warrants [Member] \| Cardinal Health 414 [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares		10,000,000
Class of Warrant or Right, Grants in Period, Estimated Fair Value						$ 3,300,000
Series NN Warrants [Member] \| UCSD [Member]
Class of Warrant or Right, Term	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares	1,000,000	1,000,000				1,000,000				1,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares	$ 1.50
Class of Warrant or Right, Grants in Period, Estimated Fair Value						$ 334,000
Former Executive [Member]
Accounts Payable, Disputed						96,000	$ 894,000			$ 96,000
Chief Executive Officer [Member] \| Employee Stock Option [Member] \| Scenario, Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures \| shares			5,000,000
GDS Business [Member
Disposal Group, Including Discontinued Operation, Consideration												$ 30,300,000
Maximum Royalty Income										$ 20,000,000
Royalty Revenue, Net						$ 0	$ 0	$ 759,000	$ 0
Royalty Revenue, Gross								1,200,000
Royalty Revenue, Tax Effect Allocated to Discontinued Operations								$ 436,000